Quintiles made it official on Feb. 15, filing to raise up to $600 million in an IPO after months of rumors and speculation. Quintiles, in part, handles contract research and strategic planning services for medical device and diagnostics companies, and clinical trial testing services for drug makers. The North Carolina company reported a $2.77 billion equity value as of March 2012, Reuters reports. Bain Capital and TPG Capital back the company, including other private equity investors. Quintiles attracted Morgan Stanley, Barclays, and J.P. Morgan Chase as lead underwriters. Story